low-risk inflect clear tavr momentum
continu concern earli
guidanc commentari still see opportun lever
earn year progress pascal ramp slower
commentari trend model pt
tavr deliv bull case edward deliv organ growth
mse driven tavr growth mse procedur
volum world-wide confirm low risk inflect follow data
recent low risk label expans tavr guidanc rang increas
comfort discuss mitral deliv
vs mse pascal remain constrain control roll-out
premium price strategi new dynam emerg
discuss mitral guidanc model
vs prior surgic growth vs mse increas
tavr volum off-set mix shift higher asp inspiri valv guidanc
remain unchang comfort midpoint critic
deliv growth line mse driven hemospher
manag increas underli guidanc busi start
look durabl earn deliv vs mse rais
guidanc comfort close high
end rang pleas see exhibit exhibit quarterli varianc
full model chang
deeper dive tavr believ clear low-risk inflect global
phenomenon us tavr deliv organ growth pt momentum
acceler ex us tavr deliv organ growth pt momentum
bp larg impli bolu volum seen continu
commentari suggest share dynam larg stabl even physician
dilig begin point coronari access benefit driver
share shift low-risk mix shift price larg stabl manag
expect continu remain disciplin even light new competitor
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
focu shift sustain growth manag
commentari point doubl digit growth repres
pessimist view recent momentum rather account tougher
comp increment competit pressur emb prudent
conservat like tale two halv due tougher comp
underli comp-adjust basi assum momentum carri
comfort underli ww tavr growth
quickli forget guidanc alarm
concert effort manag control expect reduc stock
volatil recent quarterli guidanc earli outlook clear
strategi control expect improv prior period think
expect prudent set low doubl digit tavr growth
discuss expect manag highlight put take
analyst day decemb similar last year call modest price
competit launch headwind off-set low-risk driven volum new
center add ncd lesser extent ultra roll-out rais
tavr sale p/l commentari prove littl
controversi believ reflect anyth differ desir
drive modest leverag continu invest busi
notwithstand drive ep growth excess revenu tougher
task fx driven gm sbc tailwind fade
manag highlight would like take step
bp fx benefit partial abat
comfort bp y/i headwind
assum sg continu demonstr leverag model bp
y/i expans edward continu invest see
step saw invest could point
modest leverag model margin vs
still assum increment spend
increment
underli rate benefit sbc tax rate
assum modest tax rate bp y/i
headwind variabl pend stock perform share
said impli guidanc may impli top line point slower less
tax fx hedg benefit erod level leverag earn
seen prior year model y/i ep growth line
y/i sale growth rais ep tax slightli
higher margin better sale perform could deliv mid teen earn
tmtt yet inflect investor attent tavr low risk
inflect get reflect attent shift back mitral quickli mitral saw
modest q/q increas sale in-lin q/q
increas pascal adopt curv slower expect
guidanc cut total mitral cardioband perform
mitral remain fairli irrelev control launch ensur outcom
strategi new premium price headwind emerg factor
unexpect launch slower dilig favor
manag outlook encourag broader
roll-out center drive util comfort
mitral sale driven larg major pascal remain less
sanguin cardioband discuss
clinic pipelin updat mostli in-lin edward begin three us
pivot trial ye sapien progress pivot later year
pascal clasp iif start enrol pascal tr tricupsid regurgit
edward first tr pivot begin later year key updat
look forward addit detail analyst day decemb evoqu
still earli human trial cardioband earli tavr cardioband still
undergo devic procedur optim mitral tricuspid
unclear inflect year devic mitral earli
tavr finish enrol vs next phase adopt
asymptomat sever stenos popul key sustain doubl
low-risk inflect materi pt thesi rest two
dynam low-risk pascal inflect pascal seem
driver low-risk driven inflect tavr post-superior data see
materi faster expect accret multipl
increas pt prior base base case
ep impli base case ep support dcf
methodolog includ valu mitral
tavr market expans continu low risk mitral catalyst
tavr market expans continu low risk mitral catalyst
price-to-earnings base analysi earn support
discount cash flow model assum wacc termin
growth model project tavr market growth
billion drive ebit margin incorpor
valu reflect mitral option
edward maintain share market share tavr market grow
bn tavr increasingli becom therapi choic even low
risk patient drive penetr global mitral innov progress
faster expect price declin lower expect rate
price-to-earnings base analysi equival base ep support
price-to-earnings base analysi equival base ep support
tavr market reach bn global see gradual expans
low risk popul follow low risk data complement
growth rate higher risk us eu popul ew share declin
time remain market leader coapt result mitral path
forward key edward trial timelin launch need addit clariti
oper leverag acceler long-term margin reach
risk prove bridg far valv durabl remain oustand issu
younger patient still tavr market grow billion
limit low risk intermedi risk traction sapien share slip
traction acceler competit boston off-set
peer
long-term potenti market expans
lower risk patient remain
underappreci drive
out-performance time see market
expans billion said
near term intermedi risk penetr
durabl reflect growth inflect
continu see increment
ebitda margin tavr sale
drive long-term corpor ebit margin
high near term reinvest like
mitral visibl remain low faster
develop could support bull case
project robust mitral opportun
potenti market size aortic
market discount heavili base
case reflect signific uncertainti
futur market
penetr tavr lower risk
popul critic near term
increas visibl structur heart
portfolio key durabl long term growth
risk data
risk achiev price
acceler competit
us near term robust
commerci traction boston
abbott/st jude long term
potenti pipelin develop failur
mitral space market
opportun could larger aortic
least sever year away
reimburs structur us
europ could put downward pressur
price time
million except ep
sale
sale
sale
sale
equival
prepaid expens ca
net chang work capit
oper
invest intang asset
invest unconsolid affili
proce asset disposit
proce sale busi
proce note receiv
invest
proce issuanc long-term debt
payment long-term debt
proce issuanc short-term debt
payment short-term debt
chang equiti net tax benefit
payment relat ar securit net
financ
effect currenc exchang
